Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$190.8MCash on Hand
50.1mo Cash Runway
Follow NBP by emailGet an email when NBP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NBP, unsubscribe in one click. Privacy
📣 What NBP Says Is Next
second half of 2026 · “It is expected to advance to a randomized, controlled, dose-determining Phase 2b study in the second half of 2026, with anticipated initiation of a global Phase 3 program in 2027.”
Company press release, Aug 20, 2026 · SEC filing
year end 2026 · “NovaBridge expects to initiate a Phase 3 registrational study under a potential Accelerated Approval Pathway as early as year end 2026.”
Company press release, Aug 20, 2026 · SEC filing
in 2028 · “Based on its current operating plan, the Company believes its cash position is sufficient to support the advancement of its portfolio through multiple anticipated clinical and strategic milestones, including givastomig’s planned Phase 3 interim data read-out in 2028.”
Company press release, Aug 20, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Oct 28, 2026 ·
Leadership NovaBridge appointed Chuck Silberstein as Chief Financial Officer effective November 2, 2026, succeeding Kyler Lei, who resigned effective October 30, 2026. The company said the resignation was not due to any disagreement. Form 6-K · SEC filing · Press release
Oct 26, 2026 ·
Clinical trial Updated Phase 1b givastomig data at ESMO 2026 show an objective response rate of 79% (23/29) and median progression-free survival of 16.9 months at the 8 mg/kg dose, with the company selecting that dose for registrational development. Form 6-K · SEC filing · Press release
Oct 13, 2026 ·
Deal Visara, a majority-owned NovaBridge subsidiary, licensed VIS-102 (HT006.2.2), a modified nerve growth factor for neurotrophic keratitis, from Wuhan Hiteck worldwide excluding Greater China. Visara pays $7.0 million upfront and near-term, up to $104.0 million in milestones, and single-digit tiered royalties. Form 6-K · SEC filing · Press release
Sep 8, 2026 ·
Leadership NovaBridge appointed Martin Dewhurst as an independent director, effective September 8, 2026, and to its Audit and Compensation Committees. The appointment follows the departure of director Liu Xin from the Board. Form 6-K · SEC filing · Press release
Sep 8, 2026 ·
Shareholder vote Shareholders approved an ordinary resolution removing Ms. Xin Liu as a director with immediate effect at the annual general meeting held September 8, 2026, with 107,925,508 votes for, 13,313,327 against and 55,453 abstentions. Form 6-K · SEC filing
Aug 20, 2026 ·
NovaBridge Biosciences furnished an August 20, 2026 investor presentation as Exhibit 99.1, outlining its strategy to in-license differentiated early-stage assets, largely from China, and advance them through clinical proof-of-concept. Form 6-K · SEC filing · Press release
Aug 20, 2026 ·
Earnings Reported first half 2026 cash, equivalents, short-term investments and equity investment at fair value of $215.9 million as of June 30, 2026. R&D expense rose to $14.3 million from $4.1 million, and administrative expense rose to $26.4 million from $8.3 million. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
NBP holds $190.8M in cash and short-term investments and burns about $11.4M/quarter from operations,
an estimated runway of 50.1 months at that rate (BioRadar estimate, not company guidance).
Share count 265,377,891 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NBP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NBP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.